PlainPatent
USPTO 2015–2025 USPTO PatentsView Foreign Corporation

ProQR Therapeutics II B.V.

USPTO PatentsView assignee record - 24 granted patents across 4 technology areas, recorded in grant years 2017–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Proqr ranks #12,634 of 49,997 tracked US assignees by granted-patent volume, with 24 patents across 4 technology areas.

#12,634
of 49,997 US assignees by volume
Top 50%
by Innovation Score (35.3/100)
18.5
avg claims per patent
+500%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R12634 · Foreign Corporation #12,634 · 24 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

  • GRANTS-SMALL 24 grants
  • MID-PACK #12,634/49,997
  • PHOTO-FINISH Pointr
  • CPC-NARROW C12N · 4 areas
  • INNOV-THIN 35.3/100
  • CLAIMS-RICH 18.5 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-SURGE +500% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Pointr Limited (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Proqr’s 35.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Proqr

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Proqr's Innovation Score is 35.3/100 (top 50% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Proqr?

Each dot is one of Proqr’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Proqr’s own 18.5 claims/patent is ABOVE the 16.8 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Proqr vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 23.923.92424.1 510152025 Granted patents (volume) Avg claims / patent Pointr Limited - 24, 19.96PointrPowerVision, Inc. - 24, 12.5PowervisionPremier Dental Products Company - 24, 18.08Premier Dental Pr…PricewaterhouseCoopers LLP - 24, 20.04Pricewaterhouseco…Professional Compounding Centers of America - 24, 11.46Professional Comp…Proteostasis Therapeutics, Inc. - 24, 18.21Proteostasis Ther…Rachio, Inc. - 24, 16.83RachioRade TECNOLOGÍAS S.L. - 24, 8.54Rade TecnologÍAS…ProQR Therapeutics II B.V. - 24, 18.5Proqr Therapeutic…
Proqr vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Proqr's grants concentrate

ProQR Therapeutics II B.V. is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2021 (5 grants) versus a trough of 1 in 2017. By volume, Proqr sits between Pointr Limited and Rade TECNOLOGÍAS S.L..

Proqr's three-year grant acceleration

ProQR Therapeutics II B.V. shows 9 grants in 2022–2024 against only 10 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at ProQR's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows ProQR holds 24 patents at rank #12,634, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near ProQR

By rank, the assignees closest to #12,634 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in ProQR's primary technology class.

Proqr's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 Top 50% higher than 50% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0123456 201720182019202020212022202320242025 3
USPTO utility patent grants by year · 2017–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table
ProQR Therapeutics II B.V. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2017 1 4.2%
2018 1 4.2%
2019 1 4.2%
2020 4 16.7%
2021 5 20.8%
2022 2 8.3%
2023 3 12.5%
2024 4 16.7%
2025partial year 3 12.5%

Which technologies does ProQR Therapeutics II B.V. patent most?

Top 4 of 4 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

ProQR Therapeutics II B.V.'s patent record in context - here's where to go next.

  • ProQR Therapeutics II B.V.'s lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 100% of its portfolio - see every assignee active in that class. Explore C12N
  • Ranked #12,634 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare ProQR Therapeutics II B.V. against Pointr Limited, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 35.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.